tbuckley/cabot-search huggingface dataset:
SAT0128 Biologic Treatment is Associated with More Serious Adverse Reactions, Serious Infections and Admissions in Hospital than DMARDS in Patients with Rheumatoid Arthritis: A REAL World Study
Authors: C.E. Lampropoulos, F. Orfanos, V.-K. Bournia, T. Karatsourakis, K. Mavragani, D. Pikazis, M. Manousakis, A. Tzioufas, H.M. Moutsopoulos, P.G. Vlachoyiannopoulos
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis (RA) is a systemic disease of small and large joints with many extra-articular manifestations. Biologic agents (BAs) offer a better outcome when disease is not adequately controlled by DMARDs. Nevertheless, many doubts still exist about the safety of BAs compared to classical treatment. <h3>Objectives</h3> To estimate the safety of BAs compared to DMARDs in this real world study at a single rheumatologic center. <h3>Methods</h3> This is a retrospective study of 1.494 patients9 files (1.173 women and 321 men, mean age at disease initiation 48.9 years). Demographic and clinical data were recorded during every patient9s visit. Adverse reactions (ARs) were classified according to the international CTCAE (Common Terminology Criteria for Adverse Events) system: scale 1 to 5 with parallel increase of severity (1=mild AR without any intervention, 2=medial severity with non-invasive treatment, 3=serious AR but not life-threatening, 4=serious, life-threatening AR and 5=death). <h3>Results</h3> There were 1471 patients with DMARDs administration during their follow-up (65.5 months/patient, 8037 patient-years) and 471 patients with BAs (43.5 months/patient, 1711 patient-years). During DMARDs administration there were totally recorded 908 ARs, 81 infections, 45 admissions (18 due to infections) and 58 serious ARs (CTCAE=3-5). In patients with BAs, there were totally recorded 579 ARs, 195 infections, 84 admissions (40 due to infections) and 89 serious ARs. Of patients with DMARDs, 34.9% had at least one AR (95% CI 0.323-0.376, std error 0.135) compared to 54.7% of patients with BAs (95% CI 0.503-0.592, std error 0.229). Statistical analysis showed that BAs had significantly much more ARs compared to DMARDs (p&lt;0.0001). Direct comparison between DMARDs and BAs (per 100 patient-years) showed 11.3 vs. 33.8 total ARs, 1.0 vs. 11.4 infections, 0.72 vs. 5.2 serious ARs, 0.56 vs. 4.9 admissions and 0.23 vs. 2.34 admissions due to infections, respectively. <h3>Conclusions</h3> Biologic treatment appears to have more frequent and devastating ARs compared to DMARDs in this real world study of our clinic. Further studies are needed to confirm these results, where co-morbidities and other predictive factors must be taken into account. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4694
Can we simplify terminology in the endoscopic treatment of superficial gastrointestinal neoplasia? Yes, we can.
Authors: L. Cipolletta, G. Rotondano, M. Bianco
Journal: Endoscopy (2010)

We have read with great interest the papers by Cao et al. [1] and Yoshida et al. [2] on the outcomes of mucosectomy and submucosal dissection of early colorectal neoplasia. The proliferation of different definitions (“mucosectomy,” “submucosectomy,” “submucosal dissection” etc.), in our opinion, has generated some confusion, almost as if they referred to different procedures. We believe that it might be useful to refer to these procedures using the single term of “endoscopic resection.” This term should comprehensively include all the different terminologies adopted to date, from polypectomy to submucosal dissection, which, indeed, do merely represent diverse technical modalities for performing the same procedure.
Abstract 1445: Growth inhibitory and anti-metastatic effects of the hexane/ethanol extract of <i>Glycyrrhiza uralensis</i> in a mouse breast cancer xenograft model
Authors: So Young Park, Sujin Kwon, Heesook Park, Soon Sung Lim, Jin Kyu Kim, Jong-Sang Kim, Choonghwan Lee, Jung Han Yoon Park
Journal: Cancer Research (2010)

Abstract Glycyrrhiza uralensis (licorice) is one of the most frequently prescribed ingredients in Oriental medicine and licorice root extracts have previously been shown to exhibit anti-carcinogenic activities. However, these extracts harbor considerable quantities of glycyrrhizin, which is known to exert anticarcinogenic activities and to induce severe hypokalemia and hypertension. In this study, we evaluated the effects of the hexane/ethanol extract of Glycyrrhiza uralensis (HEGU), which lacks glycyrrhizin, on the metastatic characteristics of 4T1 murine mammary carcinoma cells. When 4T1 cells were cultured on a transwell-filter in an in vitro cell culture model, HEGU inhibited cell migration and adhesion in a dose-dependent manner. Gelatin zymography and Western blot analysis showed that HEGU significantly suppressed the secretion and activation of the matrix metalloproteinase (MMP)-2 and MMP-9. The secretion of tissue inhibitor of metalloproteinase (TIMP)-1 was reduced in HEGU-treated cells. HEGU reduced the protein levels of intercellular adhesion molecule and vascular cell adhesion molecule. To assess the effects of HEGU on lung metastasis in vivo, we injected 4T1 cells (5×104 cells) into the inguinal mammary fat pads of syngeneic, immunocompetent BALB/c mice. One week after 4T1 cell injection, the mice were given HEGU (5 mg/kg body weight/day) in the drinking water for 25 days. HEGU treatment inhibited the solid tumor growth and the number of pulmonary tumor nodules. Immunohistochemistry results revealed that HEGU treatment reduced the expression of CD31, vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen and cyclin-dependent kinase 4 in the tumor tissues. In addition, the serum concentrations of MMP-9 and VEGF were decreased in the sera of mice treated with HEGU. In the present study, we have demonstrated in both in vivo and in vitro systems that HEGU greatly inhibits the growth and lung metastasis of 4T1 cells, which was accompanied by reduced levels of MMPs, adhesion molecules and VEGF. These data suggest that HEGU possesses chemotherapeutic efficacy against breast cancer including the growth of tumor and inhibition of metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1445.
Hepatic Lesion Differentiated From Accessory Spleen by a Heat-Damaged Red Blood Cell Scan
Authors: RICHARD E. PERSON, JUDITH M. BENDER
Journal: Clinical Nuclear Medicine (2000)

A 34-year-old woman referred for evaluation of an abdominal mass underwent a computed tomographic portagram that showed a large mass in the region of the left hepatic lobe and adjacent to the spleen. A liver–spleen scan with sulfur colloid did not clearly show whether the mass originated in the liver or the spleen. To evaluate the possibility of an accessory spleen, a selective spleen scan using Tc-99m–labeled heat-damaged red blood cells was performed and showed intense uptake in the region of the spleen only. The patient underwent surgical exploration and excision of the lesion, which proved to be focal nodular hyperplasia of the liver. Thus, the heat-damaged red blood cell scan ruled out an accessory spleen as a cause for the mass.
PTH-137 Patients’ views on their Experience of the Delivery of Single-Sex Accommodation within the Endoscopy Department: is it Worth it?
Authors: E F Wiseman, S Shah, Y S Ang, R R Keld
Journal: Gut (2013)

<h3>Introduction</h3> The 2007 Chief Nursing Officer’s report on privacy and dignity identified provision of single-sex accommodation (SSA) as a key objective for the NHS. This was formalised in the 2010 Department of Health (DOH) policy to eliminate mixed-sex accommodation and financial sanctions for policy breaches were introduced in 2011. Our endoscopy department adopted the policy in 2011. However the unit, which opened in 2004, has only one recovery bay, necessitating separate gender lists. Urgent procedures for patients of the opposite sex to the list running are accommodated by admission/recovery in a separate endoscopy room. We explored the views of patients on their experience of attending our unit since implementation of the SSA policy. There are no published studies of patients’ perspectives of care in endoscopy units since the widespread adoption of the policy in 2011. <h3>Methods</h3> Patients attending the endoscopy unit between August and October 2012 were invited to take part in the study by nursing staff during the admission process. Patient views were assessed using a structured non-disguised questionnaire of ten closed-ended questions. The Student’s <i>t</i>-test was used and a p value of &lt; 0.05 was taken to be significant. <h3>Results</h3> Of the 68 questionnaires returned (female 20, male 25, unknown 23) 14 (20.6% [80% female]) and 17 (25% [81.8% female]) reported that they would feel vulnerable changing behind a curtain or waiting in a gown in a mixed-sex area respectively. Patients ranked (scale 1–10, 1 = least, 10 = most) the importance of provision of SSA significantly lower than the importance of access to prompt investigation and treatment (mean: 4.8 [SD ± 3.74] <i>vs</i> 8.71 [SD ± 2.70], p = 2.6 x10–7). Male patients ranked the importance of SSA significantly lower than females (mean:1.5 [SD ±1.05] <i>vs</i> 6.5 [SD ±3.30], p = 6.3 x10–6). 17/68 patients (25%) were admitted to an area other than the main receiving/recovery area because they were a different sex to the list running, and of these, 7/17 (41.2%) felt their care was compromised or patient experience reduced as a result. <h3>Conclusion</h3> SSA delivery is important to our patients, especially women. However they rank prompt investigation and treatment as more important. The rapid introduction of SSA in our hospital, in the absence of the necessary infrastructure, conflicts in part, with the pressure to deliver timely investigations. This can lead to compromised care, notably in patients who are admitted/recovered in an alternative room and can also lead to delays for specialised endoscopy (polypectomy, ERCP and EUS). By making such compromises we are at risk of achieving no net gain in patient satisfaction and experience. <h3>Disclosure of Interest</h3> None Declared.
Abstract IA15: Measuring evolution in neoplasms
Authors: Carlo C. Malev
Journal: Cancer Research (2011)

Abstract Neoplastic progression is a process of somatic evolution, yet few evolutionary tools have been adapted to measure the dynamics of progression. We have recently shown that traditional analyses of cross-sectional sampling of neoplasms usually infers the wrong order of events in progression. In contrast, phylogenetic methods applied to multiple samples within a neoplasm can accurately infer the order of events. Furthermore, longitudinal sampling can be used to estimate mutation rates, including chromosomal aberration rates, using phylogenetic methods developed to study viral evolution in vivo. We have applied these tools to study the dynamics of progression in Barrett's esophagus and the effects of non-steroidal anti-inflammatory drugs on that somatic evolution. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr IA15.
Clinical Efficacy of EUS Evaluation in patients with Suspicious Gallbladder Wall Lesions
Authors: SH Lee, JK Ryu, YT Kim, YB Yoon, JK Park, SM Woo, JW Yoo
Journal: Endoscopy (2006)

Introduction: Differential diagnosis is often difficult for suspicious gallbladder (GB) wall lesions. The purpose of this study was to evaluate the efficacy of endoscopic ultrasonography (EUS) in the differential diagnosis of suspicious GB wall lesions. Methods: Preoperative EUS evaluation with transabdominal ultrasonography and abdominal computed tomography was done in 22 patients who underwent cholecystectomy because neoplastic GB wall lesions could not be ruled out between March 2005 and February 2006 in Seoul National University Hospital. We retrospectively reviewed the medical records. Results: Age of 22 patients was mean 56.5±14.7 years. Among them, 13 were male. The pathologic evaluation revealed cholesterol polyp in 3 patients, adenomyomatosis in 1 patient, adenoma in 2 patients, adenocarcinoma in 7 patients and chronic inflammatory change in 9 patients. Preoperative diagnosis for the GB wall lesions was correct only in 6 of 22 patients (27.2%) without EUS evaluation. However, preoperative evaluation supplemented by EUS more correctly diagnosed the gallbladder wall lesions (59.1%, 13/22) (p<0.05). Furthermore, preoperative evaluation with EUS for differentiation of neoplastic lesions from others was more correct (72.7%, 5/12) than without EUS (45.4%, 10/22) (p<0.01). And, preoperative EUS evaluation correctly diagnosed the GB wall lesions in 5 (71.4%) of 7 patients with gallstones and in 8 (53.3%) of 15 patients without gallstones, however, statistical differences was not significant (p=0.65). In addition, gallstones did not influenced on differentiation neoplastic lesions from others with EUS (p=0.82). Conclusions: EUS was effective in differential diagnosis of suspicious GB wall lesions regardless of the presence of gallstones. So, EUS could be recommended when neoplastic lesions could not be ruled out in patients with suspicious GB wall lesions.
MAGNITUDE OF BLOOD PRESSURE REDUCTION IN THE PLACEBO ARMS OF MODERN HYPERTENSION TRIALS: IMPLICATIONS FOR TRIALS OF RENAL DENERVATION
Authors: Hitesh Patel, Carl Hayward, Baris Ata Ozdemir, Stuart Rosen, Henry Krum, Alexander Lyon, Darrel Francis, Carlo Di Mario
Journal: Journal of the American College of Cardiology (2015)
Abstract 4854: Inhibition of high-mobility group box 1 protein (HMGB1) release sensitizes cancer cells to chemotherapy
Authors: Daolin Tang, Rui Kang, Herbert J. Zeh, Michael T. Lotze
Journal: Cancer Research (2010)

Abstract Metabolic and therapeutic stress can simultaneously provoke both adaptive and apoptotic responses in cancer cells. The sum of these programmed signals determines the fate of the cell: cell death or cell survival. As the catalogue of defects in pathways that control apoptosis in human tumors is expanding, understanding the significance of the alternative stress fate, autophagy, has become increasingly important. High-mobility group box 1 protein (HMGB1) is a highly conserved nuclear protein, acting as an architectural chromatin-binding factor that bends DNA and promotes protein assembly on specific DNA targets. In addition to its intranuclear roles, HMGB1 was also discovered recently to function as an extracellular signaling molecule during inflammation, cell differentiation, cell migration, and tumor metastasis. Ethyl pyruvate was first identified as an experimental agent that ameliorated inflammation, significantly reducing circulating levels of HMGB1 in animals with sepsis. Similarly, glycyrrhizin was identified as a direct small-molecule inhibitor of HMGB1 release and activity. To determine whether inhibition of HMGB1 release sensitizes cancer cells to chemotherapy, we pretreated cell with ethyl pyruvate or glycyrrhizin. These inhibitors attenuated melphalan-induced HMGB1 release. Moreover, inhibition of HMGB1 decreased autophagy by microtubule-associated protein 1 light chain 3 (LC3) puncta and LC3-II/p62 levels assay, and increased apoptosis by flow cytometry and cleaved-poly (ADP-ribose) polymerase (PARP) assays in Panc2.03 and HCT116 tumor cells when treated with chemotherapy. To further characterize the role of HMGB1 release in cancer cells following chemotherapy, a target-specific short hairpin RNA (shRNA) to HMGB1 was transferred into Panc2.03 and HCT116 tumor cells. Transfection of HMGB1-shRNA led to a significant decrease in HMGB1 protein as well as release in these cells. Depletion of HMGB1 by shRNA in these cells decreased autophagy and rendered them significantly more sensitive to melphalan-induced apoptotic cell death. Thust HMGB1 release links autophagy and apoptosis, and serves as a potential drug target for therapeutic intervention. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4854.
Morecambe Bay trust is criticised for lack of openness about complaints
Authors: C. Dyer
Journal: BMJ (2014)

Lack of openness and honesty by Morecambe Bay Hospitals NHS Foundation Trust caused “unnecessary pain and further distress” to a family that had already suffered from the tragic and avoidable death of their baby, England’s parliamentary and health service ombudsman has concluded.1

Julie Mellor found the trust guilty of maladministration in its investigation into the death of Joshua Titcombe from pneumococcal septicaemia nine days after his birth at Furness General Hospital in October 2008.

In an echo of recommendations from Robert Francis QC’s inquiry into systemic failings at Mid Staffordshire NHS Foundation Trust, Mellor demanded cultural change “from the ward to the board” to bring openness and transparency into the handling of complaints by hospitals and the wider healthcare …
41The cardiac protease-activated receptor 2 expression is crucial for the maintenance of the cardiac function in the aged heart
Authors: A Weithaeuser, K Savvatis, HP Schultheiss, U Rauch
Journal: Cardiovascular Research (2014)

Purpose: Elderly patients often suffer from left ventricular hypertrophy and diastolic dysfunction with preserved systolic function resulting from ongoing cardiomyocyte loss and cardiac fibrosis. The protease activated receptor (PAR) 2 is known to be a pro-fibrotic mediator. In a mouse model of myocardial infarction PAR2 overexpression in cardiomyocytes led to the development of fibrosis. In this study we examine the role of PAR2 in the aged heart regarding fibrosis and hemodynamic function.
Stat Bite Trends in Prostate Cancer Incidence and Surgery
Authors: Ray M. Merrill
Journal: JNCI Journal of the National Cancer Institute (1996)

tect the rights of the individuals against society's interests.The senator also said the bill draws on the recommendations made by the NIH-sponsored Ethical, Legal, and Social Implications Working Group and the National Action Plan on Breast Cancer.An identical measure was introduced by Rep. Clifford Stearns (R-Fla.).The Genetic Information Nondiscrimination in Health Insurance Act of 1995, introduced by Rep. Louise Slaughter (D-N.Y.), would prohibit insurance providers from denying or canceling health insurance coverage, or denying premiums, terms, or conditions for health insurance coverage on the basis of genetic information or on the basis that an individual or family has requested or received genetic services.The measure also establishes limitations on the collection and disclosure of genetic information.
Prospective Evaluation of Neurotoxicity in Breast Cancer Patients Treated with Adjuvant Paclitaxel.
Authors: K. Crew, L. Weimer, L. Brafman, D. Fuentes, D. Awad, D. Hershman
Journal: Cancer Research (2009)

Abstract Background: Taxanes are increasingly used in the treatment of early stage breast cancer (BC). Up to 30% of patients develop moderate-severe neurotoxicity during treatment. We recently reported that about 60% of BC patients complain of some neuropathy up to 2 years after completing adjuvant paclitaxel treatment. The prevalence, severity, and natural history of this syndrome have not been well described.Methods: Using a prospective cohort study design, women with stage I-III breast cancer undergoing adjuvant paclitaxel were enrolled. At baseline, 4 and 8 weeks during treatment, then 3, 6 and 12 months after finishing treatment, all patients completed the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) and quantitative neurosensory testing (touch perception and vibration threshold) was conducted. The FACT-Tax includes a 16-item subscale with components for neurotoxicity (11 items) and other taxane-related symptoms (5 questions), where lower scores represent worsening symptoms. Missing data was imputed. We used descriptive statistics, t-test and analysis of variance statistics.Results: A total of 50 patients enrolled, however only 41 are evaluable; median age: 47 (32-78); White/Hispanic/Black: 19/16/6; median BMI (kg/m2): 28 (21-44); stage I/II/III: 5/21/9. Mean self-reported scores on the Neurotoxicity component of the FACT-Tax decreased from 37.5 at baseline to a low of 24.8 at week 8 (p=0.0002). These scores remained lower than baseline at 6 and 12 months after completing paclitaxel treatment (32.0 and 32.4, respectively). Similar trends were seen with the Taxane component (P=0.001).The percentage of patients that reported any hand numbness increased from 14% at baseline to 57% at 8 weeks; while foot numbness increased from 20% to 72% in this timeframe. In both groups, 40% reported persistent symptoms at 12 months. Compared to baseline, there was a significant decrease in vibration sense at 8 weeks during active treatment in the great toe (p&amp;lt;0.01), but only small, clinically insignificant changes in the fingers. No significant change from baseline was seen in touch perception.Discussion: The majority of BC patients receiving adjuvant taxanes develop moderate to severe self-reported numbness and discomfort during active treatment, which improves but remains below baseline up to 12 months later. Similar, but less impressive trends were seen with quantitative neurosensory testing. Taxane-based chemotherapy has been shown to improve survival, however, neurotoxicity is the main long-term side effect. Understanding the appropriate measures to be used in interventions to prevent and treat taxane-induced neuropathy are critical. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 807.
TCTAP A-169 Long-Term Outcomes After Percutaneous Transluminal Renal Artery Stenting for Atherosclerotic Renal Artery Stenosis in the Coronary Drug-Eluting Stent Era: A Japanese Single-Center Retrospective Study
Authors: Tetsuya Ishikawa, Makoto Muto
Journal: Journal of the American College of Cardiology (2015)
More patients are waiting for hospital treatment, and for longer
Authors: G. Iacobucci
Journal: BMJ (2014)

The growing pressure on elective services at hospitals in England has been laid bare by new figures showing that over 360 000 more people were waiting for inpatient or outpatient treatment in January 2014 than in the same month last year.

The latest quarterly monitoring report from the healthcare think tank the King’s Fund shows that 9.6% of patients waited longer than 18 weeks for inpatient treatment in January.1 Although this was just within the target for 90% of inpatients to be seen within 18 weeks of referral, this is the highest proportion of patients waiting longer than 19 weeks since June 2011.

The report …
Births after Intracytoplasmic Injection of Sperm Obtained by Testicular Extraction from Men with Nonmosaic Klinefelter's Syndrome
Authors: Gianpiero D. Palermo, Peter N. Schlegel, E. Scott Sills, Lucinda L. Veeck, Nikica Zaninovic, Silvia Menendez, Zev Rosenwaks
Journal: New England Journal of Medicine (1998)

Klinefelter's syndrome is a form of hypergonadotropic hypogonadism and infertility resulting from a supernumerary X chromosome (47,XXY), with an incidence of approximately 1 case in 500 phenotypic males.1,2 Some men with Klinefelter's syndrome who have chromosomal mosaicism (46,XY/47,XXY) are fertile. Men with nonmosaic, or complete, Klinefelter's syndrome usually have azoospermia, and only a few have any spermatogenesis.3,4 Intracytoplasmic sperm injection, in which a spermatozoon is injected into an ovum in vitro, is an effective treatment for male-factor infertility. However, the complete absence of spermatozoa presents a particular clinical challenge. Postorchitis atrophy and genetic anomalies are the main causes . . .